Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
نویسندگان
چکیده
Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine has a more potent and sustained antiviral activity with a lower frequency of viral resistance than lamivudine. Although there are several reports concerning the safety profile of telbivudine, most adverse events are described as mild and transient in nature. Here we report two cases of telbivudine-induced myopathy in patients with chronic hepatitis B who were siblings.
منابع مشابه
Clinicopathological Features of Telbivudine-Associated Myopathy
Telbivudine, a thymidine nucleoside analog, is a common therapeutic option for chronic hepatitis B infection. While raised serum creatine kinase is common, myopathy associated with telbivudine is rare. Reports on its myopathological features are few and immunohistochemical analyses of inflammatory cell infiltrates have not been previously described. We describe the clinical, myopathological and...
متن کاملVitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)
α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...
متن کاملEfficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy
BACKGROUND A 2-year roadmap study was conducted to evaluate the efficacy and safety of tenofovir intensification at Week 24 in patients with chronic hepatitis B (CHB) receiving telbivudine. SCOPE A prospective multicenter study was conducted in treatment-naive patients with hepatitis B e antigen (HBeAg)-positive CHB. All patients received telbivudine (600 mg/day) until Week 24. Thereafter, pa...
متن کاملSafety evaluation of telbivudine.
IMPORTANCE OF THE FIELD Successful treatment of chronic hepatitis B (CHB) often requires long-term oral nucleoside/nucleotide agents which can be associated with viral resistance, patient non-compliance and adverse effects. Telbivudine is one of the more potent options available, with a 6.5- to 6.6-log copies/ml hepatitis B DNA reduction at 12 weeks in an early viral kinetic study, a potency co...
متن کاملAdverse effects of oral antiviral therapy in chronic hepatitis B
Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The aim of this article is to review and update the adverse effects of oral NAs. NAs can cause class...
متن کامل